Integrated BioFoundry DBTL: BioFoundry (ultrahigh-speed microbial breeding) DBTL: Elementary technology utilization Scale-up process development In-house product development Intestinal microbiome model
A startup developing kidney disease treatments and cell therapies using iPS cell technology, expanding its achievements in the kidney disease field while advancing applications to the liver and pancreas.
Development of cancer treatment equipment using optical electromagnetic waves
As a drug discovery venture originating from Kyoto University, we are developing RN-501, a novel boron-containing drug for boron-neutron capture therapy (BNCT), a next-generation cancer radiation therapy targeting intractable cancers. Through proprietary boron carbide nanoparticle technology and polyglycerol modification, RN-501 achieves high tumor selectivity and accumulation, along with potent cancer-killing and immune-activating effects with a single intravenous administration, overcoming the limitations of existing drugs. As Japan's first and the world's first nano-BNCT drug, we aim for early societal implementation.
A startup developing proprietary technology that utilizes fish-derived gut bacteria to enhance aquaculture fish growth and strengthen immunity. Centered on aquaculture support through bacterial cocktails, it also tackles land-based aquaculture and branded fish production.